Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)



Status:Archived
Conditions:Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:July 2010
End Date:November 2013

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder


This will be a multicenter, randomized, double-blind study designed to assess the efficacy,
safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in subjects
with MDD who have demonstrated an incomplete response to a prospective trial of
Escitalopram, and report a treatment history for the current MDD episode of an inadequate
response to at least one and no more than three adequate trials of an approved
antidepressant other than Escitalopram. An inadequate response is defined as less than a 50%
reduction in depressive symptom severity as assessed by the subject's self-report on the
Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and
evaluated by the investigator as part of the subject's medical and psychiatric history. An
adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or
at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.


The study will be organized as follows:

- Phase A (Screening Phase)

- Phase B (Single-blind Prospective Treatment Phase)

- Phase B+ (Single-blind Phase B Responder)

- Phase C (Double-blind Randomization Phase)

- Follow-up

Assigned Interventions:

- Phase B and Phase B+: Escitalopram monotherapy (10 mg or 20 mg)

- Phase C: Aripiprazole/Escitalopram combination therapy (3 mg/10 mg, 3 mg/20 mg, 6 mg/10
mg, 6 mg/20 mg, 12 mg/10 mg or 12 mg/20 mg); Aripiprazole monotherapy (3 mg, 6 mg or 12
mg); or Escitalopram monotherapy (10 mg or 20 mg)


We found this trial at
14
sites
Celebration, Florida
?
mi
from
Celebration, FL
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
Boston, Massachusetts
?
mi
from
Boston, MA
Click here to add this to my saved trials
Centralia, Illinois
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Charlotte, North Carolina
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Milwaukee, Wisconsin
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Nashville, Tennessee
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newington, Connecticut
?
mi
from
Newington, CT
Click here to add this to my saved trials
Ponca City, Oklahoma
?
mi
from
Ponca City, OK
Click here to add this to my saved trials
Richmond, Virginia
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Santa Clara, California 95051
?
mi
from
Santa Clara, CA
Click here to add this to my saved trials